Literature DB >> 111275

Selectivity of clorgyline and pargyline as inhibitors of monoamine oxidases A and B in vivo in man.

D L Murphy, S Lipper, S Slater, D Shiling.   

Abstract

During 4 weeks of treatment with clorgyline, a selective MAO-A inhibitor, platelet monoamine oxidase (MAO) activity was unchanged. During a similar 4-week crossover treatment period with pargyline, a selective MAO-B inhibitor, platelet MAO activity was essentially completely inhibited in the same individuals. The differential effects of the two drugs on platelet MAO, which consists exclusively of the MAO-B form, suggests that the in vitro selectivity of clorgyline, and possibly of pargyline, on MAO-A and MAO-B may be maintained in vivo during long-term administration in man. Reductions in blood pressure, heart rate, and plasma amine oxidase activity were generally similar in magnitude during treatment with both drugs, however, suggesting that either these effects are nonspecific consequences of both MAO-A and MAO-B inhibition, or that pargyline also inhibited MAO-A activity.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 111275     DOI: 10.1007/bf00427125

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  19 in total

Review 1.  Multiple forms of monoamine oxidase: fact and artefact.

Authors:  M D Houslay; K F Tipton
Journal:  Life Sci       Date:  1976-08-15       Impact factor: 5.037

2.  Treatment of hospitalized depressed and schizophrenic patients with monoamine oxidase inhibitors: including reflections on pargyline.

Authors:  J C SAUNDERS
Journal:  Ann N Y Acad Sci       Date:  1963-07-08       Impact factor: 5.691

3.  Substrate- and inhibitor-related characteristics of human platelet monoamine oxidase.

Authors:  C H Donnelly; D L Murphy
Journal:  Biochem Pharmacol       Date:  1977-05-01       Impact factor: 5.858

Review 4.  Substrate-selective monoamine oxidases--inhibitor, tissue, species and functional differences.

Authors:  D L Murphy
Journal:  Biochem Pharmacol       Date:  1978       Impact factor: 5.858

5.  Comparative trial of a new mono-amine oxidase inhibitor in depression.

Authors:  D Wheatley
Journal:  Br J Psychiatry       Date:  1970-11       Impact factor: 9.319

6.  Multiple forms of monoamine oxidase in intact mitochondria as characterized by selective inhibitors and thermal stability: a comparison of eight mammalian species.

Authors:  R F Squires
Journal:  Adv Biochem Psychopharmacol       Date:  1972

7.  Some observations upon a new inhibitor of monoamine oxidase in brain tissue.

Authors:  J P Johnston
Journal:  Biochem Pharmacol       Date:  1968-07       Impact factor: 5.858

8.  Occurrence, transport, and storage of octopamine in human thrombocytes.

Authors:  D L Murphy; D H Cahan; P B Molinoff
Journal:  Clin Pharmacol Ther       Date:  1975-11       Impact factor: 6.875

9.  Metabolism of phenylethylamine in rat isolated perfused lung: evidence for monoamine oxidase 'type B' in lung.

Authors:  Y S Bakhle; M B Youdim
Journal:  Br J Pharmacol       Date:  1976-01       Impact factor: 8.739

10.  Comparative behavioral effects of clorgyline and pargyline in man: a preliminary evaluation.

Authors:  S Lipper; D L Murphy; S Slater; M S Buchsbaum
Journal:  Psychopharmacology (Berl)       Date:  1979-04-11       Impact factor: 4.530

View more
  9 in total

Review 1.  Serotonin and blood pressure regulation.

Authors:  Stephanie W Watts; Shaun F Morrison; Robert Patrick Davis; Susan M Barman
Journal:  Pharmacol Rev       Date:  2012-03-08       Impact factor: 25.468

2.  Selective inhibition of MAO-A, not MAO-B, results in antidepressant-like effects on DRL 72-s behavior.

Authors:  G J Marek; L S Seiden
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

3.  Comparative behavioral effects of clorgyline and pargyline in man: a preliminary evaluation.

Authors:  S Lipper; D L Murphy; S Slater; M S Buchsbaum
Journal:  Psychopharmacology (Berl)       Date:  1979-04-11       Impact factor: 4.530

Review 4.  Roles of selected non-P450 human oxidoreductase enzymes in protective and toxic effects of chemicals: review and compilation of reactions.

Authors:  Slobodan P Rendić; Rachel D Crouch; F Peter Guengerich
Journal:  Arch Toxicol       Date:  2022-06-01       Impact factor: 6.168

5.  Rhesus monkey cerebrospinal fluid amine metabolite changes following treatment with the reversible monoamine oxidase type-A inhibitor cimoxatone.

Authors:  N A Garrick; T Seppala; M Linnoila; D L Murphy
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

6.  Tyramine infusions and selective monoamine oxidase inhibitor treatment. II. Interrelationships among pressor sensitivity changes, platelet MAO inhibition, and plasma MHPG reduction.

Authors:  D Pickar; R M Cohen; D C Jimerson; C R Lake; D L Murphy
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

7.  Tyramine infusions and selective monoamine oxidase inhibitor treatment. I. Changes in pressor sensitivity.

Authors:  D Pickar; R M Cohen; D C Jimerson; D L Murphy
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

8.  REM sleep suppression induced by selective monoamine oxidase inhibitors.

Authors:  R M Cohen; D Pickar; D Garnett; S Lipper; J C Gillin; D L Murphy
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

9.  Effect of selective monoamine oxidase inhibition by clorgyline and deprenyl on the norepinephrine receptor-coupled adenylate cyclase system in rat cortex.

Authors:  R Mishra; D D Gillespie; M B Youdim; F Sulser
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.